Crohn's Disease - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Crohn's Disease - Pipeline Review, H2 2013 market report to its offering
Crohn's Disease - Pipeline Review, H2 2013


, 'Crohn's Disease - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Crohn's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Crohn's Disease. Crohn's Disease - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Crohn's Disease.
- A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Crohn's Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Johnson & Johnson
Osiris Therapeutics, Inc.
Sequella, Inc.
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc
Inovio Biomedical Corporation
AbGenomics International, Inc.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
Celltrion, Inc.
Biocon Limited
Pfizer Inc.
Teva Pharmaceutical Industries Limited
Celgene Corporation
iCo Therapeutics Inc.
Enzo Biochem, Inc.
NPS Pharmaceuticals, Inc.
Ore Pharmaceuticals Inc
Soligenix, Inc.
ProMetic Life Sciences Inc.
Galapagos NV
Alba Therapeutics Corporation
Farmacija d.o.o. Tuzla
Pieris AG
Neovacs SA
Hutchison MediPharma Limited
Viropro Inc.
Oncodesign SA
Tillotts Pharma AG
Allozyne, Inc.
Coronado Biosciences, Inc.
Orphagen Pharmaceuticals, Inc.
Zealand Pharma A/S
NovImmune SA
Txcell SA
Selexys Pharmaceuticals Corporation
TcL Pharma SAS
Xencor, Inc.
Giuliani S.p.A.
Winston Pharmaceuticals, Inc.
S.L.A. Pharma AG
Medestea Research & Production S.p.A.
Stelic Institute & Co.
Antibe Therapeutics, Inc.
CLL Pharma
Amunix, Inc.
Protagonist Therapeutics, Inc.
Alfa Wassermann S.p.A
Altheus Therapeutics, Inc.
Sigmoid Pharma.

To view the table of contents for this market research report please visit